Complete suite of modern patient, prescriber, and national data products
for today¡¯s complex therapies
Compass Prescriber includes HCP-level projections for more than 4,000 brands
and their prescriptions and procedures
PLEASANTON, CA ¡ª Jan. 30, 2024 ¡ª ³Ô¹Ï±¬ÁÏ Systems (NYSE: VEEV) today announced the availability of the full ³Ô¹Ï±¬ÁÏ Compass Suite of commercial data products for a more complete view into patient populations and HCP-level insight. ³Ô¹Ï±¬ÁÏ Compass Prescriber and ³Ô¹Ï±¬ÁÏ Compass National are the first to deliver projections for both retail prescriptions and complex procedures, including in-office administered therapies, injections, and infusions. ³Ô¹Ï±¬ÁÏ Compass Suite also includes Compass Patient, granular, longitudinal patient data spanning prescriptions, procedures, and diagnoses. ³Ô¹Ï±¬ÁÏ Compass products are licensed by the brand and give brands unlimited data access, including historical data.
¡°³Ô¹Ï±¬ÁÏ Compass Suite delivers the data the industry needs for a faster, more precise approach to commercialization,¡± said Mike Rifflard, vice president, operations, rare disease, ANI Pharmaceuticals. ¡°With ³Ô¹Ï±¬ÁÏ Compass, we accelerated our product launch by giving field teams a more complete and timely view of our customers.¡±
³Ô¹Ï±¬ÁÏ Compass data products are available for the U.S. market today and include:
- ³Ô¹Ï±¬ÁÏ Compass Patient provides granular, anonymous patient data, including prescriptions, procedures, and diagnoses for market assessment, patient journey analytics, patient finding, HCP segmentation and targeting, and triggers and alerts.
- ³Ô¹Ï±¬ÁÏ Compass Prescriber includes projected prescriptions and procedures data at the HCP, HCO, and zip code levels for HCP segmentation and targeting, field planning, incentive compensation, and competitive intelligence.
- ³Ô¹Ï±¬ÁÏ Compass National is projected prescriptions and procedures data at the state and national levels for forecasting, market share tracking, and commercial strategy.
¡°The availability of the full ³Ô¹Ï±¬ÁÏ Compass Suite of data products is a major milestone for the industry and for ³Ô¹Ï±¬ÁÏ,¡± said Peter Stark, executive vice president and general manager, ³Ô¹Ï±¬ÁÏ Compass. ¡°We are excited to deliver significant innovations in commercial data for life sciences. Powered by a simple, modern data architecture, ³Ô¹Ï±¬ÁÏ Compass handles both retail and complex therapies for more than 4,000 brands.¡±
Additional Information
For more on ³Ô¹Ï±¬ÁÏ Compass, visit: veeva.com/Compass
Connect with ³Ô¹Ï±¬ÁÏ on LinkedIn:
About ³Ô¹Ï±¬ÁÏ Systems
³Ô¹Ï±¬ÁÏ is the global leader in cloud software for the life sciences industry. Committed to innovation, product excellence, and customer success, ³Ô¹Ï±¬ÁÏ serves more than 1,000 customers, ranging from the world¡¯s largest biopharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, ³Ô¹Ï±¬ÁÏ is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit veeva.com.
³Ô¹Ï±¬ÁÏ Forward-looking Statements
This release contains forward-looking statements regarding ³Ô¹Ï±¬ÁÏ¡¯s products and services and the expected results or benefits from use of our products and services. These statements are based on our current expectations. Actual results could differ materially from those provided in this release and we have no obligation to update such statements. There are numerous risks that have the potential to negatively impact our results, including the risks and uncertainties disclosed in our filing on Form 10-Q for the period ended October 31, 2023, which you can find (a summary of risks which may impact our business can be found on pages 38 and 39), and in our subsequent SEC filings, which you can access at .
###
Contact:
Alison Borris
³Ô¹Ï±¬ÁÏ Systems
925-226-8821
alison.borris@veeva.com